Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15213909 | 1.00 | KDM4E (0.33) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL17816746 | 1.00 | KDM4E (0.33) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL21923888 | 0.99 | KDM4E (0.33) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL21558986 | 0.99 | KDM4E (0.33) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL17854094 | 0.99 | KDM4E (0.34) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL19530816 | 0.98 | KDM4E (0.33) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL21924571 | 0.98 | KDM4E (0.33) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL17854213 | 0.98 | KDM4E (0.33) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL18468740 | 0.98 | KDM4E (0.35) | KDM4EMEN1LMNAMAPTOPRK1 | |
| SCHEMBL25563017 | 0.97 | PDK2 (0.33) | KDM4EMEN1LMNAMAPTOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10944057-B2 | Compound, material for organic electroluminescence devices, organic electroluminescence device, and electronic equipment | IDEMITSU KOSAN CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20180190904-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20160176801-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICES, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
| US-20160176801-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICES, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT | IDEMITSU KOSAN CO., LTD. (JP) | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10944057-B2 | Compound, material for organic electroluminescence devices, organic electroluminescence device, and electronic equipment | OR10J3, KCNA5, KCNK10 | KDM4E 783/4885MEN1 796/4885LMNA 638/4885 |
| US-20180190904-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | ESR1, L1CAM, ELAVL1 | KDM4E 864/4885MEN1 349/4885LMNA 527/4885 |
| US-20160176801-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENCE DEVICES, ORGANIC ELECTROLUMINESCENCE DEVICE, AND ELECTRONIC EQUIPMENT | OR10J3, KCNA5, KCNK10 | KDM4E 783/4885MEN1 796/4885LMNA 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.